Skip to Content


MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

Main Content

Plenary Session 2202

The Neurobiology of Parkinson's Disease

Saturday, September 28, 2024
11:00 - 13:00 | Ballroom AB

In this session, the faculty will discuss current proposals, evidence and challenges in biologically defining and classifying Parkinson's disease.

Oscar Gershanik, Argentina
Brit Mollenhauer, Germany


The Role of a-synuclein in the Neurobiology of Parkinson’s Disease
Eng-King Tan, Singapore

Parkinson’s Disease Without a-synuclein: The Elephant in the Room
Jeffrey Kordower, USA

Current Proposals and Future Directions for Re-defining and Classifying Parkinson's Disease
Lorraine Kalia, Canada

CSPC Liaisons:
Claudia Trenkwalder, Germany

Learning Objectives
At the conclusion of this session, participants should be better able to:

  1. Describe supporting evidence suggesting a-synuclein as the main determinant in the pathogenesis of Parkinson’s disease
  2. Describe evidence against a-synuclein as the main determinant in the pathogenesis of Parkinson’s disease
  3. Explain the current proposals and challenges for a biological definition and classification of Parkinson’s disease

Recommended Audience
Fellow / Resident / Student
Researcher / Basic Science

Education Level
Beginner / Foundational
Experienced / Intermediate
Expert / Advanced

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including and This cookie policy only covers the primary and domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice